NAGE
Niagen Bioscience Inc
NAGE offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over NAGE overall, supported by stronger fundamentals and stronger modeled upside.
NAGE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Strong |
NAGE's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NAGE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $2.05 | -3.7% |
| Current | 18x | $2.13 | — |
| Fair | 27x | $3.30 | +55% |
| Expensive | 79x | $9.47 | +345% |
| Forward | 217x | $2.13 | — |
Historical ranges are pointers, not guarantees.
NAGE's PE is in its cheap range at 18x. Analysts expect earnings to fall, which would put today's price at 217x next year's earnings, in its expensive range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NAGE in the historical PE scenario, which offers more potential upside but is not a forecast.
NAGE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NAGE's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over NAGE on the outlook, with more favorable valuation and earnings expectations.
NAGE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | -92% |
| Q3 2026 | $0.12 | -52% |
| Q2 2026 | $0.18 | -18% |
| Q1 2026 | $0.21 | +17% |
| Q4 2025 | $0.20 | +82% |
| Q3 2025 | $0.25 | +2400% |
| Q2 2025 | $0.22 | +$0.24 |
| Q1 2025 | $0.18 | +$0.23 |
| Q4 2024 | $0.11 | +$0.18 |
NAGE has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NAGE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.2M | -20% |
| Q2 2026 | $29.8M | -4.3% |
| Q1 2026 | $31.5M | +3.3% |
| Q4 2025 | $33.8M | +16% |
| Q3 2025 | $34M | +33% |
| Q2 2025 | $31.1M | +37% |
| Q1 2025 | $30.5M | +38% |
| Q4 2024 | $29.1M | +37% |
NAGE's revenue fell from its 2025 peak and has held roughly level since: $27M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.8% | -18 points |
| Q2 2026 | 2.4% | -7.9 points |
| Q1 2026 | 5% | -11 points |
| Q4 2025 | 12% | -12 points |
| Q3 2025 | 12% | +6.2 points |
| Q2 2025 | 10% | +11 points |
| Q1 2025 | 16% | +19 points |
| Q4 2024 | 24% | +25 points |
NAGE's operating margin was −5.8% last quarter, down 18 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NAGE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NAGE on profitability, with a higher operating margin.
NAGE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6M | -29% |
| Q2 2026 | $2.8M | +122% |
| Q1 2026 | -$1.2M | -115% |
| Q4 2025 | $679K | -92% |
| Q3 2025 | $3.7M | +5.6% |
| Q2 2025 | $1.3M | +$1.5M |
| Q1 2025 | $7.9M | +2572% |
| Q4 2024 | $8.6M | +1222% |
NAGE still generates free cash flow, though less than at its 2024 peak: $5M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NAGE on cash flow, with more consistent year-over-year improvement.
NAGE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -3.4M shares |
| 1 year | -8.6% | -7.5M shares |
| 3 years | +5.5% | +4.1M shares |
| 5 years | +16% | +10.9M shares |
| Available history | +28% | +17.5M shares |
NAGE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $2.8M |
| Q1 2026 | $2.4M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NAGE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -11.9x | Net Cash |
| Q2 2026 | -5.8x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -3.8x | Net Cash |
| Q3 2025 | -3.2x | Net Cash |
| Q2 2025 | -3.5x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -5.2x | Net Cash |
NAGE has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NAGE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 3.5 | Oversold |
NAGE's weekly RSI is 23 (oversold) and its Stochastic is 4 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NAGE PE vs Healthcare Sector
| Metric | NAGE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 22 | 29 | 7 pts below |
NAGE is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over NAGE on valuation relative to its sector.
NAGE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.50 | 15% below |
| 20 week MA | $2.93 | 27% below |
| 50 week MA | $4.14 | 49% below |
| 100 week MA | $6.23 | 66% below |
| 200 week MA | $4.35 | 51% below |
NAGE is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NAGE on trend strength, trading above more of its moving averages.
NAGE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.47 | $4.99 | +12% |
| 2021 | $4.99 | $4.13 | -17% |
| 2022 | $4.13 | $1.50 | -64% |
| 2023 | $1.50 | $1.43 | -4.7% |
| 2024 | $1.43 | $5.52 | +286% |
| 2025 | $5.52 | $6.64 | +20% |
| 2026 YTD | $6.64 | $2.13 | -68% |
NAGE's yearly returns have swung widely, from +286% in 2024 to −64% in 2022. It's down 68% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NAGE on returns for 2026, with the stronger performance.